Author Insight
Pregnenolone and Resting-State Amygdala Connectivity in Women With Major Depressive Disorder
E. Sherwood Brown, MD, and Francesca Filbey, PhD, describe the background for a neuroimaging study of pregnenolone in women with major depressive disorder. The video focuses on resting-state fMRI findings across placebo, 500 mg/day, and 800 mg/day pregnenolone conditions.
November 20, 2026
Watch the Author InsightE. Sherwood Brown, MD, and Francesca Filbey, PhD, describe the rationale and resting-state fMRI findings from a neuroimaging study of pregnenolone in women with major depressive disorder.
Author Insight
In this video, E. Sherwood Brown, MD, introduces pregnenolone and describes why his group became interested in it. He notes that pregnenolone was first available as an oral preparation in the 1940s, that it is produced from cholesterol, and that every other steroid hormone in the human body is made through long metabolic pathways beginning with pregnenolone. He also describes several related neurosteroids and states that the clinical evidence for pregnenolone itself is preliminary, while noting promising findings from randomized double-blind, placebo-controlled trials in mood disorders and adjunctive therapy findings in negative symptoms of schizophrenia.
Francesca Filbey, PhD, then presents the neuroimaging findings, which demonstrated how pregnenolone is associated with differences in functional brain connectivity in women with major depressive disorder. She describes the rationale for focusing on emotional processing and cognitive control circuits, particularly interactions between the amygdala and prefrontal regions, and situates the work in relation to prior neuroimaging findings involving neurosteroid administration.
The investigators used a randomized double-blind, placebo-controlled crossover design in which each participant received 500 milligrams per day of pregnenolone, 800 milligrams per day, and placebo for seven days each, with a 14 day washout period between conditions. In 11 women with complete usable imaging data across all three conditions, predefined region-to-region analyses did not identify significant differences between treatment conditions, but whole brain seed-to-voxel analysis showed that, compared with placebo, 500 milligrams was associated with reductions in functional connectivity between the bilateral amygdala and the left frontal pole. No significant difference was observed between 800 milligrams and placebo, and amygdala frontal pole connectivity was significantly higher following 800 milligrams compared with 500 milligrams.
Key Takeaways
- Pregnenolone is produced from cholesterol, and every other steroid hormone in the human body is made through long metabolic pathways beginning with pregnenolone.
- Pregnenolone itself acts as a modulator of the cannabinoid CB1 receptor and also appears to have interactions with microtubule-associated proteins.
- The neuroimaging report used a randomized double-blind, placebo-controlled crossover design in which each participant received 500 milligrams per day of pregnenolone, 800 milligrams per day, and placebo, each for seven days with a 14 day washout period between conditions.
- In 11 women with complete usable imaging data, predefined region-to-region analyses did not identify significant differences between treatment conditions.
- Compared with placebo, 500 milligrams of pregnenolone was associated with reductions in functional connectivity between the bilateral amygdala and the left frontal pole, while no significant difference was observed between 800 milligrams and placebo.
These findings suggest that differences in functional connectivity associated with pregnenolone administration may not increase linearly with dose.
From Psychiatrist.com
Sign up for the JCP Digest
We send one focused email per month. No spam — unsubscribe anytime.